Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients

Garnier, J. L.; Chevallier, Philippe; Dubernard, Jean Michel; Trépo, Christian; Touraine, J. L.; Chossegros, P.

doi:10.1016/s0041-1345(96)00100-5

Cited by 56 publications

(23 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interferon increases the risk of rejection in renal transplant patients because it is a strong immunomodulatory drug enhancing T lymphocyte-related cytotoxicity and natural killer functions. We obtained no virological response to ribavirin monotherapy, contrary to what is reported in the literature [4]. However, there was a tendency to a decrease in transaminase levels compared to the values at the beginning of therapy, and in only 1 patient did they decrease to the normal range.…”

contrasting

confidence: 99%

Ribavirin Treatment in Patients with Chronic Hepatitis C Infection Who Had Renal Transplantation

Karaca¹,

Beşışık²,

Akyüz³

et al. 2005

Dig Surg

View full text Add to dashboard Cite

contrasting

confidence: 99%

Ribavirin Treatment in Patients with Chronic Hepatitis C Infection Who Had Renal Transplantation

Karaca¹,

Beşışık²,

Akyüz³

et al. 2005

Dig Surg

View full text Add to dashboard Cite

“…This trial has demonstrated that, despite the impaired clearance of ribavirin in patients with renal dysfunction, the drug could still be used safely if its dose is reduced and if its plasma concentrations and hemoglobin levels are closely monitored (69). Treatment with ribavirin alone has failed to clear HCV RNA in renal transplant recipients, but has been found to cause a drop in HCV RNA titers by 70-82% in 57% of the patients, and has not been associated with any detrimental side-effects on graft function (70). More data are needed before ribavirin can be recommended as part of the therapeutic regimens for the treatment of HCV infection in patients with advanced impairment of renal function or in those on renal replacement therapy.…”

Section: Management Of Hcv In Renal Transplant Patientsmentioning

confidence: 99%

Management of Hepatitis C Infection in Renal Transplant Recipients

Natov

Pereira

2002

American Journal of Transplantation

View full text Add to dashboard Cite

“…Similarly, small studies that assessed ribavirin monotherapy in kidney transplant recipients reported improved serum aminotransferase levels, but no significant reduction in the rate of fibrosis progression, and persistence of HCV infection in all patients (113,117,118). Therefore, there is no role for ribavirin monotherapy in the management of HCV disease in kidney transplant recipients.…”

Section: Ribavirin Monotherapymentioning

confidence: 99%

The Kidney Transplant Recipient with Hepatitis C Infection

Terrault

Adey

2007

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Liver disease secondary to chronic hepatitis C virus (HCV) infection is an important cause of morbidity and mortality in dialysis patients and kidney transplant recipients. Evaluation of patients with chronic HCV infection is warranted to determine stage of disease and the need for HCV therapy. Although combination therapy with interferon (IFN) plus ribavirin is the standard of care for chronic HCV infection, IFN monotherapy is recommended in dialysis patients because ribavirin is contraindicated in the presence of renal failure. The goals of pretransplantation HCV therapy are to decrease the risk for progression of HCV-associated liver disease, stabilize renal function in patients with HCV-related glomerulopathy, and prevent development of HCV-associated renal disease after transplantation. Posttransplantation HCV therapy is generally not recommended because of concerns regarding risk for precipitating acute rejection; however, antiviral therapy may be indicated to treat HCV-related glomerulopathy or prevent progression of chronic hepatitis C in patients with more advanced stages of fibrosis. When treatment is required, restored renal function allows use of combination therapy with IFN and ribavirin. Limitations of current HCV therapy include lack of tolerability and suboptimal response rates. New antiviral agents that can be used in dialysis patients (e.g., ribavirin alternatives) and in the posttransplantation setting (e.g., IFN alternatives) are needed to improve outcomes in these populations.

show abstract

Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients

Cited by 56 publications

References 1 publication

Ribavirin Treatment in Patients with Chronic Hepatitis C Infection Who Had Renal Transplantation

Ribavirin Treatment in Patients with Chronic Hepatitis C Infection Who Had Renal Transplantation

Management of Hepatitis C Infection in Renal Transplant Recipients

The Kidney Transplant Recipient with Hepatitis C Infection

Contact Info

Product

Resources

About